Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Completed · Phase 2

Conditions studied: Melanoma (Skin), Metastatic Cancer

In brief

RATIONALE: Colony-stimulating factors, such as sargramostim, may help the body's immune system to kill cancer cells. Giving sargramostim in different ways may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of sargramostim given as a breathing treatment for treating patients who have melanoma that is metastatic to the lung.

Key facts

Study ID
NCT00005610
Run by
Alliance for Clinical Trials in Oncology
People needed
28
Starts
2000-09-01
Expected to finish
2006-06-01
Last updated by the study team
2016-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.